Post on 10-Apr-2018
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 1 of 37
Title: TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with
Broad Anti-Tumor Activity and Minimal Erythrocyte Binding
Authors/Affiliations: Penka S. Petrova1, Natasja Nielsen Viller1, Mark Wong1, Xinli
Pang1, Gloria H. Y. Lin1, Karen Dodge1, Vien Chai1, Hui Chen1, Vivian Lee1, Violetta
House1, Noel T. Vigo1, Debbie Jin1, Tapfuma Mutukura1, Marilyse Charbonneau1, Tran
Truong1, Stephane Viau1, Lisa D. Johnson1, Emma Linderoth1, Eric L. Sievers1, Saman
Maleki Vareki2,3, Rene Figueredo2,3, Macarena Pampillo2, James Koropatnick2,3, Suzanne
Trudel4, Nathan Mbong4, Liqing Jin4, Jean C.Y. Wang4,5 and Robert A. Uger1
1Trillium Therapeutics Inc., Mississauga, Ontario, Canada
2London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada
3Department of Oncology, University of Western Ontario, London, Ontario, Canada
4Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada
5Division of Medical Oncology and Hematology, Department of Medicine, UHN, and Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Running Title: TTI-621: a novel innate immune checkpoint inhibitor
Financial support: These studies were sponsored by Trillium Therapeutics Inc.,
Mississauga, Canada
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 2 of 37
Corresponding Author: Dr. Robert A. Uger, Trillium Therapeutics Inc., Mississauga, Ontario, Canada. Phone: 416-595-0627; FAX: 416-595-5835; Email: bob@trilliumtherapeutics.com
Potential Conflicts of Interest: PSP, NNV, MW, XP, GHYL, KD, VC, HC, VL, VH, NTV, DJ, TM, MC, TT, SV, LDJ, EL, ELS and RAU are employees of Trillium Therapeutics Inc. SMV, RF, MP, JK, ST, NM, LJ and JCYW have received funding support from Trillium Therapeutics Inc.
Total number of figures and tables: 6
References: 38
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 3 of 37
Translational Relevance (142 words):
SIRPαFc (TTI-621) is a novel innate immune checkpoint inhibitor designed to: 1) bind
human CD47 on tumor cells and prevent it from delivering inhibitory signals to
macrophages and 2) engage Fc gamma receptors (FcγR) expressed by macrophages to
further enhance phagocytosis. Here we show that TTI-621 avidly binds to CD47 on a
wide range of human tumor cells and selectively promotes macrophage-mediated
phagocytosis of both hematologic and solid tumor cells. Furthermore, these in vitro
effects translate into significant antitumor activity in mouse models of leukemia and
lymphoma. Importantly, unlike anti-CD47 antibodies, TTI-621 binds minimally to human
erythrocytes, minimizing potential toxicity related to hemolytic anemia. Based on the
demonstrated antitumor activity in the context of minimal erythrocyte binding, two Phase
1, multicenter studies have been initiated to evaluate TTI-621 in subjects with
relapsed/refractory hematological malignancies and solid tumors (NCT02663518 and
NCT02890368, respectively).
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 4 of 37
ABSTRACT (250 words):
Purpose: The ubiquitously expressed transmembrane glycoprotein CD47 delivers an
anti-phagocytic (do not eat) signal by binding signal-regulatory protein α (SIRPα) on
macrophages. CD47 is over-expressed in cancer cells and its expression is associated
with poor clinical outcomes. TTI-621 (SIRPαFc) is a fully human recombinant fusion
protein that blocks the CD47:SIRPα-axis by binding to human CD47 and enhancing
phagocytosis of malignant cells. Blockade of this inhibitory axis using TTI-621 has
emerged as a promising therapeutic strategy to promote tumor cell eradication.
Experimental Design: The ability of TTI-621 to promote macrophage-mediated
phagocytosis of human tumor cells was assessed using both confocal microscopy and
flow cytometry. In vivo antitumor efficacy was evaluated in xenograft and syngeneic
models and the role of the Fc region in antitumor activity was evaluated using SIRPαFc
constructs with different Fc tails.
Results: TTI-621 enhanced macrophage-mediated phagocytosis of both hematologic and
solid tumor cells, while sparing normal cells. In vivo, TTI-621 effectively controlled the
growth of aggressive AML and B lymphoma xenografts and was efficacious in a
syngeneic B lymphoma model. The IgG1 Fc tail of TTI-621 plays a critical role in its
anti-tumor activity, presumably by engaging activating Fcγ receptors on macrophages.
Finally, TTI-621 exhibits minimal binding to human erythrocytes, thereby differentiating
it from CD47 blocking antibodies.
Conclusions: These data indicate that TTI-621 is active across a broad range of human
tumors. These results further establish CD47 as a critical regulator of innate immune
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 5 of 37
surveillance and form the basis for clinical development of TTI-621 in multiple oncology
indications.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 6 of 37
INTRODUCTION
The phagocytic activity of macrophages is regulated by both activating (“eat”) and
inhibitory (“do not eat”) signals. CD47, a widely expressed transmembrane glycoprotein,
serves as a critical inhibitory signal, suppressing phagocytosis by binding to signal
regulatory protein alpha (SIRPα) on the surface of macrophages. Engagement by CD47
triggers tyrosine phosphorylation of the cytoplasmic tail of SIRPα, leading to recruitment
of the Src homology-2 domain containing protein tyrosine phosphatases SHP-1 and SHP-
2 and prevention of myosin-IIA accumulation at the phagocytic synapse (1). CD47 is
believed to regulate the natural clearance of senescent erythrocytes and platelets by
splenic macrophages (2, 3). In addition, the CD47-SIRPα interaction may represent an
important mechanism by which malignant cells escape immune-mediated clearance.
CD47 has been shown to be over-expressed in numerous hematologic malignancies,
including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic
lymphocytic leukemia (CLL), multiple myeloma, myelodysplastic syndrome (MDS), and
in multiple types of non-Hodgkin lymphoma (NHL), including diffuse large B-cell
lymphoma (DLBCL), mantle cell lymphoma, and marginal cell lymphoma (4-10).
Similarly, elevated CD47 expression has been demonstrated on solid tumors, including
bladder, brain, breast, colon, esophageal, gastric, kidney, leiomyosarcoma, liver, lung,
melanoma, ovarian, pancreatic, and prostate tumors (11-15). CD47 has been found to be
an adverse prognostic factor where high CD47 expression correlates with more
aggressive disease and poorer clinical outcomes. For example, overall survival was
significantly lower for DLBCL or mantle cell lymphoma patients who had elevated CD47
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 7 of 37
expression, and higher CD47 expression on tumor cells was associated with significantly
poorer event-free survival in patients with CLL (7). Similar trends have been reported in
other hematologic malignancies (5, 6, 8) and solid tumors (11, 13, 16, 17). Additionally,
there is evidence to suggest that increased CD47 expression is associated with the
transition from low-risk to high-risk MDS and subsequent transformation to AML (10).
These findings are consistent with tumor cells exploiting the suppressive CD47-SIRPα
axis to evade macrophage-mediated destruction. Blocking CD47 has thus emerged as a
promising therapeutic strategy and several studies have shown that interrupting the
CD47-SIRPα signaling pathway using anti-CD47 monoclonal antibodies (mAbs)
promotes anti-tumor activity against human cancers both in vitro and in vivo (6-9, 18).
However, the expression of CD47 on erythrocytes raises concerns about the potential for
anti-CD47 mAbs to cause hemolytic anemia, as seen in preclinical studies (19).
Furthermore, erythrocyte CD47 constitutes a massive antigen sink that may limit the
ability of CD47-targeting agents to reach tumor cells. Finally, CD47 targeting agents
bound to erythrocytes may cause interference with blood typing tests.
TTI-621 (SIRPαFc) is a novel innate immune checkpoint inhibitor that binds human
CD47 and prevents it from delivering a “do not eat” signal to macrophages. It is designed
to function as a decoy receptor, binding CD47 on the surface of tumor cells and blocking
its anti-phagocytic “do not eat” signal, thereby allowing macrophages to phagocytose
malignant cells. Moreover, the IgG1 Fc region of SIRPαFc can interact with human Fcγ
receptors on macrophages to further enhance phagocytosis, tumor antigen presentation,
and effective anti-tumor activity. Here, we fully characterize this novel agent and
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 8 of 37
demonstrate that TTI-621 strongly binds to a wide range of human tumors and induces
potent phagocytosis of human tumor cells in vitro and in vivo while sparing most normal
cells. Although the decoy receptor binds circulating platelets and leukocytes, TTI-621
shows only minimal binding to human erythrocytes, thereby mitigating concerns of
anemia associated with anti-CD47 mAbs. These results further establish CD47 as a
critical regulator of innate immune surveillance and form the basis for clinical
development of TTI-621 in multiple oncology indications.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 9 of 37
METHODS
SIRPαFc Proteins
TTI-621 consists of the N-terminal V domain of human SIRPα (GenBank AAH26692)
fused to the human IgG1 Fc region (hinge-CH2-CH3, UniProtKB/Swiss-Prot, P01857).
Variant proteins were generated in which the identical human SIRPα domain was linked
to a human IgG4 Fc region (hinge-CH2-CH3, UniProtKB/Swiss-Prot, P01861) or an
IgG4 Fc region which was mutated to remove residual Fc interactions (20). Both IgG4-
based fusion proteins contained a hinge-stabilizing mutation that prevents the formation
of intrachain disulfide bonds (21). Two mouse surrogate SIRPαFcs were constructed, one
using the N-terminal V domain from NOD mouse SIRPα (22) and the second using a
mutated (CV1) N-terminal V domain of human SIRPα (23). In both mouse surrogates the
SIRPα domains were linked to a mouse IgG2a Fc (hinge-CH2-CH3, UniProtKB/Swiss-
Prot, P01863). All constructs were generated by overlapping PCR using standard
molecular biology techniques and expressed in stably transfected CHO-S cells
(Invitrogen). Proteins were purified from culture supernatant using protein A and
hydrophobic interaction chromatography, concentrated and residual endotoxin removed.
Control human IgG1 and mouse IgG2a Fc proteins lacking the SIRPα domain were also
generated and similarly purified. All proteins displayed >99% purity by HPLC and <0.4
EU/mg endotoxin.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 10 of 37
Antibodies
The anti-CD47 antibodies BRIC126 (Serotec), 2D3 (eBioscience) and CC2C6
(BioLegend) were obtained from commercial sources. Clones B6H12.2 (ATCC®
HB¬9771™) and 5F9 (19) were generated internally based on publicly available
sequences. Rituximab (Hoffman-La Roche Ltd, Basel, Switzerland) was obtained from
the London Health Sciences Centre pharmacy (London, Ontario).
Cells
The following human tumor cell lines were used: DLBCL (HT, Ly1, Pfeiffer, NUDUL1,
SUDHL4, SUDHL6, SUDHL8, SUDHL16, Toledo), multiple myeloma (MM1.s, 8226,
H929, U266), non-DLBCL B-cell lymphomas (Raji, Namalwa, C1R, Ly5), AML (HL-
60, KG-1, THP-1 and TF-1, AML-2), chronic myeloid leukemia (K562, KU812), acute
T-cell leukemia (ENL-1, Jurkat), T-cell lymphoma (HH, H9, SUPT1, DERL7), lung
cancer (A549), epidermoid cancer (A431), ovarian cancer (OVCAR-3), colon cancer
(DLD-1), breast cancer (SKBR3), melanoma (A375, SK-MEL-1, G-361, WM-115, SK-
MEL-28) and Merkel cell carcinoma (MCC26, MKL-1). All cell lines were obtained
from American Type Culture Collection (ATCC) except MCC26 and MKL-1 (Sigma-
Aldrich), AML-2 (kindly provided by Mark Minden, University Health Network,
Toronto), EN-1 (kindly provided by Aaron Schimmer, University Health Network,
Toronto) and Ly5 (kindly provided by David Spanner, Sunnybrook Research Institute,
Toronto). The mouse A20 B lymphoma line was obtained from ATCC.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 11 of 37
Viably frozen primary tumor cells from the peripheral blood or bone marrow of patients
with B-cell ALL, T-cell ALL, MDS and AML were obtained from the University Health
Network (UHN) BioBank (Toronto) according to procedures approved by the Research
Ethics Board of UHN.
Human macrophages were prepared from heparinized whole blood obtained from normal
healthy human donors (Biological Specialty Corporation); informed consent was
obtained from all donors. Peripheral blood mononuclear cells (PBMCs) were isolated
over Ficoll-Paque Plus density gradient (GE Healthcare) and CD14+ monocytes were
isolated from PBMCs by positive selection using CD14 antibody-coated MicroBead
separation (Miltenyi Biotec). Monocytes were differentiated into macrophages by
culturing for at least 10 days in X-Vivo-15 media (Lonza) supplemented with M-CSF
(PeproTech). One day prior to phagocytosis assays, the monocyte-derived macrophages
were primed with IFN-γ (PeproTech) to generate M1 macrophages, or with IL-4
(Peprotech) to generate M2 macrophages. Unless otherwise specified, all phagocytosis
assays were carried out using M1 macrophages. When required, macrophages were
harvested using Enzyme-Free Cell Dissociation Buffer (ThermoFisher).
Tumor Cell Binding
Cell lines or primary patient samples were added in duplicate to 96-well plates and
incubated with titrated amounts of biotinylated TTI-621 or biotinylated isotype-matched
control IgG Fc, together with Near-IR LIVE/DEAD Fixable Dead Cell Stain (Invitrogen)
for 30 min on ice. Cells were washed, stained with phycoerythrin (PE)-conjugated
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 12 of 37
streptavidin (eBioscience), washed, and resuspended in Stabilizing Fixative (BD
Biosciences). Flow cytometry was performed on a FACSVerse flow cytometer (BD
Biosciences). Data were analyzed using FlowJo software (Treestar Inc.). Half-maximal
effective concentration (EC50) values were calculated using a sigmoidal dose-response
curve in GraphPad Prism software.
Erythrocyte Binding
Erythrocytes were isolated from sodium heparinized whole blood from healthy human
donors (Biological Specialty Corporation) by centrifugation followed by several washes
with PBS. The resulting packed erythrocytes were diluted in PBS and added in duplicate
to 96-well plates. Binding was performed by incubating erythrocytes with titrated
amounts of TTI-621, anti-CD47 monoclonal antibodies (BRIC126 (Serotec), 2D3
(eBioscience), CC2C6 (BioLegend), B6H12 (in-house), 5F9 (in-house)). Cells were
washed and subsequently stained with biotin-conjugated anti-human IgG Fc PAN
(Hybridoma Reagent Laboratory), followed by detection with PE-conjugated streptavidin
(eBioscience). Flow cytometry was performed on a FACSVerse flow cytometer (BD
Biosciences).
Hemagglutination Assays
Titrated amounts of TTI-621 or anti-CD47 mAbs (up to 3 μM) were added to wells
containing erythrocytes diluted in PBS, and the plates were incubated overnight at 37˚C
in 5% CO2. The extent of hemagglutination was assessed by scoring each well on a scale
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 13 of 37
of 1 to 6, with 1 representing the absence of hemagglutination and 6 representing
complete hemagglutination.
Phagocytosis Assays
Confocal-based phagocytosis assay: Tumor cells were labeled with CellTrace CFSE (Life
Technologies) and added to primed macrophages in 24-well plates at a 1:5 effector:target
ratio. Macrophages and tumor cells were co-cultured for 2 hours at 37˚C in 5% CO2 in
the presence of TTI-621 or control Fc protein and subsequently stained with Alexa Fluor
555-conjugated Wheat Germ Agglutinin (Invitrogen). Phagocytosis was assessed by
confocal microscopy on a Quorum Wave FX-X1 Spinning Disc Confocal System and
images were analyzed using Velocity software (PerkinElmer). A phagocytosis index was
calculated as: (number of tumor cells inside macrophages/number of macrophages) x
100; counting at least 200 macrophages per sample. All tumor cells counted were
confirmed to be internalized using z-stack images. Statistical significance was calculated
by unpaired t-test vs isotype control using GraphPad Prism software.
Flow cytometry-based phagocytosis assay: Tumor cells were labeled with Violet
Proliferation Dye 450 (BD Biosciences) and added to primed macrophages in 96-well
plates at a 1:5 effector:target ratio. Macrophages and tumor cells were co-cultured for
2 hours at 37˚C in 5% CO2 in the presence of TTI-621 or control Fc protein and
subsequently stained with Near-IR LIVE/DEAD Fixable Dead Cell Stain (Invitrogen),
APC-conjugated anti-human CD14 (61D3, eBioscience) and PE-conjugated anti-human
CD11b (ICRF44, eBioscience), washed and resuspended in Stabilizing Fixative (BD
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 14 of 37
Biosciences). Cells were acquired on a FACSVerse flow cytometer, and data were
analyzed using FlowJo software (Treestar Inc.). Macrophages were identified as live,
single, CD14+CD11b+ cells. Doublets were excluded by SSC-W and SSC-H
discrimination. Percent phagocytosis was assessed as the percent of macrophages that
were VPD450+. The gating strategy and representative dot plots are shown in
Supplementary Figure 1. Statistical significance was calculated by unpaired t-test vs
isotype control using GraphPad Prism software.
AML Xenografts
AML xenografts were performed in 10 week-old female NOD.SCID mice bred and
maintained in the Barrier Unit at the UHN Animal Facility (Toronto, Canada). One day
prior to transplantation, mice were sublethally irradiated (275 cGy) and pretreated with
anti-CD122 antibody (0.2 mg/mouse) to deplete residual host NK cells. On the day of
transplantation, viably frozen mononuclear cells collected from AML patients 90543 and
90191 were thawed, counted, and transplanted intra-femorally into the preconditioned
mice at a dose of 5×106 cells/mouse in a total volume of 30 µl. Twenty-one days after
engraftment, mice were dosed with TTI-621 (8 mg/kg) or equimolar amount of control
human IgG1 Fc (5.4 mg/kg) at 0.3 mL/mouse, 3 times/week for 4 weeks. Upon
euthanization, bone marrow from injected and non-injected bones was collected and
stained with mouse anti-human antibodies including CD47-FITC, CD33-PE, CD19-PC5,
CD45-APC, CD34-APCCy7, CD38-PECy7. After staining, washed cells were run on an
LSRII flow cytometer (BD). 10,000 to 20,000 events were collected for each sample.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 15 of 37
Collected data were analyzed by FlowJo software to assess AML engraftment levels in
the injected femur, non-injected bones, and in the spleen as determined by the percentage
of human CD45+CD33+ cells.
B Cell Lymphoma Xenografts
Lymphoma xenografts were performed in 6 to 7 week-old female NOD.Cg-
PrkdcscidHrhr/NCrHsd (SHrN) mice, a hairless severe combined immunodeficient strain,
obtained from Harlan Laboratories (Montreal, Canada) and maintained at the Victoria
Research Laboratories Vivarium (London Health Sciences Centre). Raji and Namalwa
cells (1 x 106 per injection) were injected subcutaneously into each flank of SHrN mice in
a volume of 0.1 mL PBS (i.e., 2 tumor injection sites per mouse). Toledo cells (1 x 107
per injection) were injected in 50% Matrigel (ECM gel, Sigma-Aldrich, St. Louis, MO)
in a volume of 0.1 mL into the left flank for SHrN mice. Mice were kept under
isoflurane-mediated anesthesia during the injections. Three days after Raji and Nawalma
tumor cell implantation and 10 days after Toledo tumor cell implantation, animals
received either 10 mg/kg of mouse SIRPαFc (NOD SIRPα) or 6.75 mg/kg control IgG2a
Fc, daily 5 times per week, for 3 weeks by intraperitoneal injection. Tumor volumes were
estimated twice weekly by standard caliper measurements of length and width then
calculated as follow: π/6 x (longest diameter) x (shortest diameter)2. Tumor volumes
were monitored until they reached the maximum volume of approximately 1500 mm3 or
maximum permissible markers of discomfort in the mice were reached (i.e., mouse
discomfort or body weight loss reached maximum allowable levels), at which time the
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 16 of 37
mice were sacrificed. All studies were conducted according to the animal care guidelines
described by the Canadian Council on Animal Care (CCAC) and monitored by The
Western University Animal Use Subcommittee. Statistical significance was calculated by
two-way ANOVA using GraphPad Prism software.
Syngeneic B Cell Lymphoma Model
Female BALB/c mice (6–8 weeks old) were purchased from Charles River Laboratories
(Wilmington, MA) and housed in the University of Toronto animal facility (Mississauga,
ON). A20 cells (2x106) were injected subcutaneously into the right hind flank of 8-week-
old BALB/c female mice in a volume of 0.1mL. When the tumors were palpable
(approximately 60 mm3), they were randomized and injected intratumorally with 200 μg
(10 mg/kg) of a mouse SIRPαFc surrogate (CV1 SIRPα) fusion protein in a 50 μL
volume of PBS. Control groups were injected with vehicle alone in a 50 μL volume.
Animals were dosed twice weekly for a total of five doses. Tumors were monitored three
times a week and tumor volume was calculated as ½ length×width2. Tumor volumes were
monitored until one or more tumor dimensions reaches the maximum permissible
measure (15 mm), or when maximum permissible markers of discomfort were observed,
at which time the mice were sacrificed. All animal procedures were approved by the
animal care committee of the University of Toronto in accordance with the CCAC.
Statistical significance was calculated by two-way ANOVA using GraphPad Prism
software.
RESULTS
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 17 of 37
Structure of TTI-621
TTI-621 (SIRPαFc) was generated by directly linking the sequences encoding the
N-terminal CD47 binding domain of human SIRPα with the Fc domain of human IgG1
(Figure 1). The SIRPα region interacts with CD47, while the Fc region binds to Fcγ
receptors. TTI-621 is secreted by a genetically-engineered Chinese hamster ovary (CHO)
cell line as a 77 kDa disulfide-linked, N-glycosylated homodimer consisting of two
identical 345 amino acid chains.
TTI-621 Binds to CD47 and Enhances Macrophage Phagocytosis of Tumor Cells In
Vitro
The binding of TTI-621 to CD47 on malignant human cells was assessed by flow
cytometry. TTI-621 was found to bind strongly to a panel of 19 tumor cell lines derived
from patients representing a wide range of both hematologic and solid tumors
(Supplementary Table 1). TTI-621 also exhibited strong binding to primary tumor
samples obtained from the blood of patients with B cell acute lymphoblastic leukemia (B-
ALL), T-ALL and AML, and bone marrow samples from patients with MDS, with an
average binding EC50 value of 197 ± 182 nM (Supplementary Table 2). CD47 is widely
expressed on normal cells, and TTI-621 also demonstrated binding to human CD4+ T
cells, CD8+ T cells, B cells, platelets, natural killer (NK) cells, granulocytes, monocytes
and NK T cells from the peripheral blood of healthy donors (Supplementary Table 3).
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 18 of 37
The ability of TTI-621 to promote macrophage-mediated phagocytosis of human tumor
cells was assessed using both confocal microscopy and flow cytometry. Monocyte-
derived macrophages were co-cultured with tumor cells for two hours, and in cultures left
untreated or treated with a control Fc fragment, macrophages exhibited a low level of
phagocytosis, consistent with CD47-mediated suppression. In contrast, blockade of CD47
on the target cells using TTI-621 significantly increased macrophage phagocytosis of
tumor cells (Figure 2A). Compared to a control Fc protein, TTI-621 promoted
macrophage phagocytosis of 77% (23/30) of tumor cell lines established from patients
with hematological malignancies and 67% (8/12) of human solid cancer cell lines (Figure
2B). A marked pro-phagocytic effect of TTI-621 was also observed on primary samples
from patients with AML, MDS, multiple myeloma, B-ALL and T-ALL (Figure 2C). TTI-
621 enhanced macrophage-mediated killing of 97% (32/33) of primary blood cancer
samples tested. Drug activity was further characterized by titrating TTI-621 on selected
human tumor cell lines (n=13) and primary tumor samples (n=4) (representative data in
Figure 2D). As summarized in Supplementary Table 4, TTI-621 treatment resulted in a
saturable, dose-dependent phagocytic response with an average EC50 of 10 ± 14 nM.
We then assessed the effect of TTI-621 on macrophage-mediated phagocytosis of normal
cells in vitro. As shown in Figure 2E, TTI-621 potently increased phagocytosis of
primary AML tumor cells, while sparing normal peripheral blood monocytes, indicating
that TTI-621-enhanced phagocytosis is tumor cell-specific.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 19 of 37
Collectively, these in vitro data demonstrate that TTI-621 induces potent, tumor-specific
macrophage phagocytosis across a broad range of hematological and solid tumors. In
fact, we have not observed a tumor type that is refractory to TTI-621 treatment,
consistent with prior data demonstrating that the CD47 immune checkpoint is widely
used by malignant cells to escape immune surveillance (5, 24).
TTI-621 and Mouse Surrogate SIRPαFc have Potent Anti-Tumor Activity In Vivo
To determine whether the potent effects of TTI-621 in vitro translated into in vivo anti-
tumor activity, we employed an AML xenograft model using primary patient samples.
Engrafted mice were treated with TTI-621 or an Fc fragment control three times/week for
four weeks. Although control-treated animals exhibited significant engraftment,
particularly in the injected bone marrow, TTI-621 treatment significantly reduced the
tumor burden in bone marrow and spleen (Figure 3A and B). In fact, tumor cells were
undetectable in most animals following TTI-621 therapy.
The presence of CD47 on non-tumor tissue has the potential to bind SIRPαFc and remove
it from circulation, potentially resulting in a significant antigen sink effect. Since TTI-621
does not bind to mouse CD47 (data not shown), TTI-621 treatment of xenograft recipient
does not model this antigen sink effect. To overcome this limitation, mouse surrogate
fusion proteins (mSIRPαFc) were constructed using the mouse IgG2a Fc region, allowing
for full effector function, analogous to the human IgG1 Fc region in TTI-621. Treatment
of mice with mSIRPαFc may thus more closely mimic the anticipated pharmacokinetic
and Fc effector activity profile of TTI-621 in human subjects. The in vivo efficacy of
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 20 of 37
mSIRPαFc was assessed in three aggressive B cell lymphoma xenograft models:
Namalwa and Raji (Burkitt lymphomas) and Toledo (DLBCL). Hairless NOD.SCID
(SHrN™) mice were implanted subcutaneously with tumor cells and treated with
mSIRPαFc five times/week for three weeks starting either three days after engraftment
(Namalwa and Raji) or 10 days after engraftment (Toledo). mSIRPαFc treatment
markedly reduced the growth of Raji tumors (Figure 3C) and completely ablated
Namalwa and Toledo tumors (Figure 3D and E); in the latter two models, most mice
remained tumor-free 60 days after inoculation. Moreover, mSIRPαFc was superior to
Rituximab therapy in both Namalwa and Toledo xenografts.
To overcome the limitations inherent with xenograft models, we also assessed whether
mSIRPαFc could reduce tumor burden in an immune-competent syngeneic system.
BALB/c mice were subcutaneously inoculated with A20 B cell lymphoma cells, and
mSIRPαFc was administered by intratumoral injection twice weekly starting seven days
post-engraftment. As shown in Figure 3F, mSIRPαFc treatment significantly reduced the
growth of A20 tumors, confirming that CD47 blockade with mSIRPαFc is also
efficacious in animals with an intact immune system.
Collectively, these in vivo data suggest that blockade of the CD47:SIRPα axis using
SIRPαFc has broad applicability across a variety of malignancies.
Blockade of CD47 using SIRPαFc Requires an IgG1 Fc Tail for Maximum Potency
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 21 of 37
Engagement of Fcγ receptors (FcγRs) on macrophages by SIRPαFc may deliver a pro-
phagocytic signal that could augment the effect of CD47 blockade. TTI-621 possesses an
IgG1 Fc tail, allowing for binding to the high-affinity receptor FcγRI (CD64) as well as
to the low-affinity receptors FcγRII (CD32) and FcγRIII (CD16). To determine whether
the IgG1 Fc tail is required for maximum potency, we compared the in vitro activity of
TTI-621 with a variant SIRPαFc in which the IgG1 Fc region of TTI-621 was replaced
with an IgG4 Fc tail. IgG4 Fc regions bind well to CD64 but have weaker interactions
than IgG1 with CD32 and CD16 (25). We compared the pro-phagocytic activity of both
SIRPαFcs using classically activated (M1) and alternatively activated (M2) macrophages.
We have previously shown that M1 macrophages are CD32hi CD64hi in vitro, whereas
M2 macrophages are CD32hi CD64lo (26). TTI-621 enhanced phagocytosis by both
macrophage subsets equally well. In contrast, SIRPαFc with an IgG4 tail induced
significantly less phagocytosis by M2 macrophages (Figure 4A). These data suggest that
an IgG1 tail is necessary for SIRPαFc’s enhancement of phagocytosis by both M1 and
M2 macrophages.
We next compared the in vivo activity of TTI-621 and the variant IgG4-containing
SIRPαFc in the AML xenograft model. We also tested a SIRPαFc with a mutated IgG4
Fc region that is completely devoid of Fc effector functions. As shown in Figure 4B,
treatment with all three SIRPαFc constructs reduced tumors to undetectable levels in the
spleen. In the injected femur and non-injected bone marrow, TTI-621 treatment
completely ablated tumor growth in all but one mouse. SIRPαFc with an IgG4 tail
reduced tumor burden in the non-injected bone marrow, but not in the injected femur
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 22 of 37
compared to controls, whereas the mutated IgG4 fusion protein was unable to control
tumor burden in either bone marrow compartment (Figure 4B).
The contribution of the Fc region raises the question of whether TTI-621 activity requires
neutralization of the CD47 “do not eat” signal, or whether it simply opsonizes CD47-
expressing cells for Fc receptor-mediated destruction, similar to antibodies that trigger
classical antibody-dependent cellular phagocytosis (ADCP). To address this, we
compared the in vitro activity of TTI-621 to two isotype-matched (mouse IgG1) anti-
CD47 antibodies: clone B6H12, which blocks the CD47-SIRPα interaction and the non-
neutralizing clone 2D3. As shown in Figure 4C, 2D3 induces a low level of phagocytosis,
attributable to opsonization of CD47 without blockade of the CD47-SIRPα interaction.
B6H12 is more effective than 2D3 at inducing the phagocytosis of a human B lymphoma
target, indicating that efficient phagocytosis in this system requires blockade of the
CD47-SIRPα interaction. TTI-621 exhibits even greater activity than B6H12, which
presumably reflects the combined effect of CD47 blockade and more effective Fc
receptor engagement by the TTI-621 human IgG1 Fc region.
Collectively, these data show that SIRPαFc with an IgG1 tail (TTI-621) is significantly
more potent at promoting phagocytosis in vitro and controlling tumor burden in vivo, and
that both CD47 blockade and Fc-mediated effector functions contribute to the mechanism
of action of TTI-621.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 23 of 37
TTI-621 Induces Anemia in Non-Human Primates But Binds Minimally to Human
Erythrocytes
A significant concern with CD47-blocking agents is related to the high expression of
CD47 on human erythrocytes and the potential for such agents to cause anemia, as seen
in preclinical studies (19). To assess the risk of anemia and other adverse events, primate
repeat-dose toxicology studies of TTI-621 were conducted in non-human primates.
Cynomolgus monkeys were selected as relevant species based on the high CD47
sequence homology (97.6% identity to human CD47) and cross-reactivity studies
The principal dose-limiting toxicity observed in cynomolgus monkeys was anemia,
which occurred at repeat doses of 3 mg/kg or greater. In addition to anemia, other
cytopenias, including thrombocytopenia, lymphopenia, neutropenia and monocytopenia
were observed, although these were reversible and without clinical sequelae (see
Supplementary Figure 2 for representative hematology values). The bone marrow
exhibited evidence of regenerative responses, notably erythropoiesis. No effects were
observed on neurologic, cardiovascular or other systems.
Despite the strong binding of TTI-621 to monkey erythrocytes, we observed only
minimal binding to human erythrocytes (Figure 5A), which may be due to species-
specific differences in the mobility of CD47 in erythrocyte membranes (data not shown).
Importantly, the low binding profile of TTI-621 to human erythrocytes is in contrast to
the strong binding demonstrated by five different anti-CD47 antibody clones (Figure 5A).
Minimal binding of TTI-621 was observed on erythrocytes from all 43 healthy donors
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 24 of 37
tested regardless of gender, ABO blood group or rhesus antigen status (Figure 5B).
Consistent with these binding data, TTI-621 did not induce hemagglutination of human
erythrocytes in vitro (Figure 5C). The lack of significant binding of TTI-621 to human
erythrocytes thus offers a significant advantage over CD47-blocking mAbs
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 25 of 37
DISCUSSION
Approved immune checkpoint inhibitors have extended the survival of multiple
subgroups of cancer patients and thus transformed modern oncology. Although the focus
thus far has been on blockade of checkpoints that suppress T cell responses (e.g., PD-1 or
PD-L1), there is growing recognition that the innate immune system plays an important
role in the initiation and propagation of enduring anti-tumor responses and CD47 has
recently emerged as a key checkpoint of innate immunity. Our findings demonstrate that
SIRPαFc (TTI-621) is an effective decoy receptor that enhances macrophage-mediated
phagocytosis in a broad spectrum of human hematologic and solid tumors, both in vitro
and in xenograft models. More than 97% of primary patient samples tested were sensitive
to the antitumor effects of TTI-621, suggesting that this therapeutic approach will have
broad applicability in human cancer.
Importantly, blockade of CD47 by TTI-621 selectively induced phagocytosis of
malignant cells over normal cells, providing a therapeutic window for treatment of
patients in the clinic. Preferential macrophage phagocytosis of AML cells over normal
cord blood/bone marrow cells has also been reported for an IgG4-based SIRPαFc fusion
protein, even when non-malignant cells outnumbered the AML cells by a 2:1 ratio (27).
In addition, a mouse anti-human CD47 neutralizing antibody did not induce phagocytosis
of normal peripheral blood B cells (7) or normal human pancreatic ductal epithelial cells
and pancreatic stellate cells (15).
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 26 of 37
The specificity for tumor cells is thought to result from the expression of pro-phagocytic
signals such as calreticulin on malignant cells but not on normal cells. Calreticulin is
known to trigger macrophage-mediated phagocytosis, and the phagocytosis of cancer
cells induced by CD47 blockade can be completely inhibited by antagonizing the
interaction between calreticulin and its receptor (28). It is hypothesized that tumor cells
evade phagocytosis because the inhibitory CD47 pathway counterbalances the pro-
phagocytic calreticulin signal. Selectively targeting CD47 with TTI-621 promotes killing
of tumor cells while sparing low calreticulin-expressing normal cells. There are likely to
be other as yet unidentified pro-phagocytic signals on tumor cells that may vary
depending on the tissue type from which the tumor is derived. The broad efficacy of TTI-
621 across tumor types suggests that targeting the CD47- SIRPα axis exploits the reliance
of tumor cells on CD47-mediated suppression of phagocytosis regardless of their specific
underlying pro-phagocytic signals.
The potent in vivo effects of TTI-621 were attenuated when the IgG1 Fc tail of the fusion
protein was substituted by an IgG4 tail with reduced Fc-mediated effector function, or
with an inert mutated IgG4 tail, indicating that Fc effector function is critical for
achieving maximum potency of SIRPαFc. These observations are consistent with a prior
report demonstrating that engineered high affinity SIRPα monomers that bind strongly to
CD47 but lack an Fc region are inactive on their own (29) and suggest that maximal anti-
tumor activity is obtained through blockade of the CD47 “do not eat” signal and
simultaneous delivery of a pro-phagocytic (“eat”) signal through macrophage FcγRs. In
line with this, our data suggest that TTI-621 does not work simply by opsonization of
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 27 of 37
CD47 and ADCP, but triggers phagocytosis through CD47 blockade as well as
simultaneous activation through FcγRs.
Although CD47 has recently emerged as a promising immuno-oncology target, concerns
have been raised regarding the potential for anemia and an erythrocyte antigen sink, due
to the expression of high levels of CD47 on human red blood cells (30, 31). In this
regard, TTI-621 exhibits an advantage over anti-CD47 antibodies, in that it binds only
minimally to human red blood cells. A similar observation has recently been reported by
an independent group (32). The minimal binding of TTI-621 to human erythrocytes may
be due to the association of CD47 with the erythrocyte spectrin cytoskeleton (30), which
results in reduced membrane mobility (33) and a consequent failure to cluster CD47
effectively. Consistent with this theory, we have previously shown strong binding of TTI-
621 to human erythrocytes when CD47 is first pre-clustered using a non-blocking CD47
antibody (34).
While it is acknowledged that TTI-621 binds to human platelets and leukocytes (and thus
may be associated with the development of thrombocytopenia and/or leukopenia), the
extremely low erythrocyte-binding profile of TTI-621 offers several potential advantages
over anti-CD47 mAbs that strongly bind to erythrocytes. First, treatment with TTI-621 is
less likely to result in anemia. CD47 is thought to protect erythrocytes from macrophage-
mediated clearance (2), and CD47 blocking antibodies are known to trigger anemia in
non-human primates, a finding that may limit their clinical utility despite the employment
of a priming strategy (19). Second, minimal erythrocyte binding permits the use of an
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 28 of 37
IgG1-based fusion protein, and thus maximizes macrophage phagocytosis of tumor cells,
without concern for opsonizing red blood cells and targeting them for destruction. Third,
CD47-targeting agents that bind erythrocytes may interfere with transfusion typing and
cross-matching tests, as seen with other agents that bind erythrocytes (35, 36). Finally,
TTI-621 is likely to have a superior pharmacokinetic profile compared to anti-CD47
mAbs by avoiding the significant antigen sink created by dense cell surface expression of
CD47 on erythrocytes, enabling more comprehensive engagement of tumor-expressed
CD47.
We demonstrated that CD47 blockade with SIRPαFc is efficacious in AML and B
lymphoma xenograft models, as well as in a B lymphoma syngeneic model.
Macrophages, in addition to their direct tumoricidal properties, function as antigen
presenting cells, and thus it is possible that enhancement of phagocytosis by TTI-621
treatment may also result in an enhanced adaptive immune response. In support of this,
CD47 antibody blockade has been shown to augment tumor antigen presentation and
priming of an anti-tumor cytotoxic CD8+ T-cell response in immune-competent mice
(37). In addition, CD47 blockade using a high-affinity SIRPα-variant-human Ig fusion
protein has also been shown to promote tumor-specific CD8+ T-cell responses through a
dendritic cell-based mechanism (38). These studies provide compelling evidence to
support the hypothesis that TTI-621 has the potential to generate an enduring anti-tumor
response by acting at the nexus of the innate and adaptive immune systems. We propose a
mechanism in which TTI-621 blocks the CD47 “do not eat” signal on tumor cells while
simultaneously delivering pro-phagocytic signals to macrophages through FcγRs, leading
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 29 of 37
to tumor cell phagocytosis, enhanced antigen presentation and stimulation of a tumor
antigen-specific T cell response (Figure 6).
In summary, these data affirm CD47 as a critical regulator of immune surveillance and
provide a strong rationale for therapeutic targeting of CD47. Simultaneous blockade of
the inhibitory signal of CD47 with an associated engagement of FcγR on macrophages
form the basis for clinical development of TTI-621. Two Phase 1, open label,
multicenter studies are currently ongoing to evaluate TTI-621 in patients with
relapsed/refractory hematological malignancies (NCT02663518) and solid tumors
(NCT02890368).
ACKNOWLEDGEMENTS
Eilidh Williamson provided medical writing assistance, under the sponsorship of Trillium
Therapeutics Inc.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 30 of 37
REFERENCES
1. Tsai RK, Discher DE. Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008;180:989-1003. 2. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288:2051-4. 3. Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005;105:3577-82. 4. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-57. 5. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271-85. 6. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Jr., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286-99. 7. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699-713. 8. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 2011;71:1374-84. 9. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26:2538-45. 10. Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2013;110:3011-6. 11. Nagahara M, Mimori K, Kataoka A, Ishii H, Tanaka F, Nakagawa T, et al. Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res. 2010;16:4625-35. 12. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A. 2012;109:6656-61.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 31 of 37
13. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012;109:6662-7. 14. Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP, et al. Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis. Mol Ther. 2013;21:1919-29. 15. Cioffi M, Trabulo S, Hidalgo M, Costello E, Greenhalf W, Erkan M, et al. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clin Cancer Res. 2015;21:2325-37. 16. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van HM, Otten MA, et al. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA. 2011;108:18342-7. 17. Steinert G, Scholch S, Niemietz T, Iwata N, Garcia SA, Behrens B, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014;74:1694-704. 18. Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118:4890-901. 19. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS ONE. 2015;10:e0137345. 20. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol. 1999;29:2613-24. 21. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993;30:105-8. 22. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007;8:1313-23. 23. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013;341:88-91. 24. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010;31:212-9. 25. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716-25. 26. Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, et al. SIRPαFc, a CD47-Blocking Cancer Immunotherapeutic, Triggers Phagocytosis of Lymphoma Cells by Both Classically (M1) and Alternatively (M2) Activated Macrophages. AACR. New Orleans; 2016.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 32 of 37
27. Theocharides AP, Jin L, Cheng PY, Prasolava TK, Malko AV, Ho JM, et al. Disruption of SIRPalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med. 2012;209:1883-99. 28. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2:63ra94. 29. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013;110:11103-8. 30. Mouro-Chanteloup I, Delaunay J, Gane P, Nicolas V, Johansen M, Brown EJ, et al. Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47. Blood. 2003;101:338-44. 31. Burger P, Hilarius-Stokman P, de KD, van den Berg TK, van BR. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood. 2012;119:5512-21. 32. Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, et al. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. Clinical Cancer Research. 2016. 33. Subramanian S, Tsai R, Sen S, Dahl KN, Discher DE. Membrane mobility and clustering of Integrin Associated Protein (IAP, CD47) - major differences between mouse and man and implications for signaling. Blood Cells Mol Dis. 2006;36:364-72. 34. Uger RA, Dodge K, Pang X, Petrova PS. Cancer immunotherapy targeting CD47: Wild type SIRPαFc is the ideal CD47-blocking agent to minimize unwanted erythrocyte binding. AACR 2014. San Diego, CA: Cancer Res; 2014. 35. Oostendorp M, Lammerts van Bueren JJ, Doshi P, Khan I, Ahmadi T, Parren PWHI, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55:1555-62. 36. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545-54. 37. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA. 2013;110:11103-8. 38. Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21:1209-15.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 33 of 37
FIGURE LEGENDS
Figure 1: Structure of TTI-621
TTI-621 consists of the N-terminal domain of human SIRPα (shown in red) linked to a
human IgG1 Fc region (shown in blue). The hinge and inter-chain disulfide bonds are
shown as black lines.
Figure 2: TTI-621 promotes macrophage-mediated phagocytosis of human tumor
cells in vitro. (A) Representative scanning confocal microscopy images after
macrophages were co-cultured with a primary AML patient sample for 2 hours in the
presence of 10 μM TTI-621 or control IgG1 Fc protein. Tumor cells and macrophages are
stained green and red, respectively. (B) Macrophage-mediated phagocytosis of
established human tumor cell lines from patients with B-cell malignancies (n=17),
myeloid malignancies (n=7), T-cell malignancies (n=6), skin cancers (n=7) and other
solid cancers (n=5) in the presence of 1 μM TTI-621 (black bars) or control IgG1 Fc
protein (white bars). Phagocytosis was quantified by determining a phagocytosis index
(number of engulfed tumor cells per 100 macrophages) using confocal microscopy or
measuring percentage phagocytosis by flow cytometry, as described in the Materials and
Methods section. (C) Macrophage-mediated phagocytosis of primary human tumor
samples from patients with hematological malignancies (n=33) in the presence of 1 μM
TTI-621 (black circles) or control IgG1 Fc protein (white circles). (D) Representative
titration of TTI-621 (black circles) on a primary AML patient sample. Control Fc protein
(white circle) was tested at 1 μM. (E) Macrophage-mediated phagocytosis of primary
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 34 of 37
AML tumor sample or normal monocytes was assessed by confocal microscopy in the
presence of 1 μM TTI-621 or control IgG1 Fc. Statistical significance was assessed by
unpaired t-test vs Fc control (*p<0.05, **p<0.01, ***p<0.001, NS=not significant).
Figure 3: TTI-621 and its mouse surrogate are efficacious in vivo. (A-B) NOD.SCID
mice were preconditioned with sublethal irradiation and anti-CD122 antibody (to deplete
residual NK cells) and then transplanted with AML cells from patient #0905443 (A) or
patient #090191 (B) by intrafemoral injection. Treatment with TTI-621 (8 mg/kg IP
3x/week for 4 weeks) or control IgG1 Fc protein was initiated 21 days post-
transplantation. The % AML engraftment (% cells expressing human CD45 and CD33
markers) was assessed by flow cytometry. Each symbol represents one mouse, bars
indicate mean values. P-values were determined by t-test vs Fc control protein. Data
shown are representative of 9 separate AML patient xenografts. (C-E) SHrN™ mice
(n=5 per group) received subcutaneously implanted Raji (C), Namalwa (D) or Toledo (E)
cells. Three days after implantation (Namalwa and Raji) or 10 days after implantation
(Toledo), mice were dosed IP with either a mouse surrogate SIRPαFc (10 mg/kg), control
mouse IgG2a Fc (6.67 mg/kg) or rituximab (8 mg/kg) five times a week for three weeks
(indicated by the arrow heads). Tumor volumes were estimated by caliper measurement
from both flanks and the means for those measurements were calculated in mm3. Mice
were sacrificed when tumor volumes exceeded 1500 mm3 or when there was extensive
ulceration. Mean tumor volumes are recorded only for time points in which ≤ 1 mouse
per group was sacrificed. Data shown are representative of 4 (Raji), 2 (Namalwa) and 2
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 35 of 37
(Toledo) independent experiments. Mice were terminated at a tumor volume of 1500
mm3 (F) 2x106 A20 cells were implanted subcutaneously into the right flank of Balb/c
mice on day 0. Mice were randomized (n=9-10 mice per treatment arm) when the mean
tumor size was palpable at which time the tumors were approximately 60 mm3 in volume.
A mouse surrogate SIRPαFc (10 mg/kg) or vehicle was given bi-weekly by intratumoral
administration. Mice were sacrificed when at least one tumor dimension exceeded 15
mm. Mean tumor volumes ± standard error of the mean were recorded only for time
points in which ≤ 2 mice per group were sacrificed. Data shown is representative of 2
independent experiments. Statistical significance was assessed by two-way ANOVA
(***p<0.001).
Figure 4: SIRPαFc with an IgG1 Fc tail has potent anti-tumor efficacy. (A) M1 and
M2 monocyte-derived macrophages were generated by priming for 24 hours with IFN-γ
or IL-4, respectively. Macrophage phagocytosis of a DLBCL cell line (Toledo) was
assessed by flow cytometry (% Phagocytosis) in the presence of SIRPαFc with an IgG1
Fc tail (TTI-621) or an IgG4 Fc tail (both at 1 μM concentration). Data shown represent
n=5 donors. (B) NOD.SCID mice were preconditioned with sublethal irradiation and
anti-CD122 antibody (to deplete residual NK cells) and then transplanted with AML cells
from patient #090191 by intrafemoral injection. Treatment with SIRPαFc (8 mg/kg IP
3x/week for 4 weeks) or control IgG1 Fc protein was initiated 21 days post-
transplantation. The % AML engraftment (% cells expressing human CD45 and CD33
markers) was assessed by flow cytometry. Each symbol represents one mouse, bars
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 36 of 37
indicate mean values. P-values were determined by one-way ANOVA. Data shown are
representative of 2 independent experiments. (C) Monocyte-derived macrophages were
generated as described and primed for 24 hours with IFN-γ. Macrophage phagocytosis of
a DLBCL cell line (Toledo) was assessed by flow cytometry (% Phagocytosis) in the
presence of TTI-621, anti-CD47 mAbs B6H12 or 2D3, or isotype-matched controls (all at
1 μM).
Figure 5: TTI-621 exhibits minimal binding to human erythrocytes. (A) Human
erythrocytes were stained with saturating concentrations of TTI-621 or CD47-specific
antibodies (clones BRIC126, 2D3, CC2C6, B6H12 or 5F9) and analyzed by flow
cytometry. Representative histograms are shown, with specific staining shown in black
and isotype control staining in grey. (B) Summary data showing the mean fluorescence
intensity for 43 erythrocyte donors. (C) Hemagglutination assays were conducted with
human erythrocytes and titrated amounts of TTI-621 or CD47-specific antibodies. The
extent of hemagglutination was assessed by blinded scoring on a scale of 1 to 6, with 1
representing the absence of hemagglutination and 6 representing complete
hemagglutination.
Figure 6: Proposed mechanism of action of TTI-621-mediated CD47 anti-tumor
activity. (A) CD47 sends an inhibitory signal to macrophages by binding to SIRPα. (B)
TTI-621 binds to CD47 on tumor cells and blocks this interaction, (C) while engaging
FcγR on macrophages, (D) leading to macrophage-mediated phagocytosis of tumor cells.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
TTI-621 is an Innate Immune Checkpoint Inhibitor with Potent Antitumor Activity
Resubmitted 17 October 2016 Page 37 of 37
(E) Macrophages that have phagocytosed target cells can present tumor peptides in the
context of MHC to tumor-specific CD8+ T cells, (F) activating the adaptive immune
response and leading to destruction of tumor cells by cytotoxic CD8+ T cells.
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
Figure 1
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
A
B
C D
No Treatment Control Fc (10 mM) SIRPαFc (10 mM)
0
1 0 0
2 0 0
3 0 0
Ph
ag
oc
yto
sis
In
de
x
C o n tro l F c
T T I-6 2 1
A M L c e lls N o rm a l M o n o c y te s
*
E
0
1 0 0
2 0 0
3 0 0
0
1 0
2 0
3 0
4 0
T C e ll M a lig n a n c ie s
Ph
ag
oc
yto
sis
In
de
x % P
ha
go
cy
tos
is
E N L -1
***
*
J u rk a t
***
**
**NS
T -A L L T L y m p h o m a
H H H 9 S U P T 1 D E R L 7
0
4 0
8 0
1 2 0
M y e lo id M a lig n a n c ie s
Ph
ag
oc
yto
sis
In
de
x
A M L -2 H L -6 0 K G -1 T H P -1 T F -1
***
***
**
***
NS
K 5 6 2 K U 8 1 2
***
*
A M L C M L
0
2 0
4 0
6 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
B C e ll M a lig n a n c ie s
Ph
ag
oc
yto
sis
In
de
x
L y 1 S 4 S 8 T oH T
***
***
***
NS
P f S 6 S 1 6N U 1
NS
***
******
***
82 N am C 1 RM M 1 H 9 R a L y 5U 2 6
* **
***
***
**NS
NS
NS
D L B C L M M N o n -D L B C L
0
5
1 0
1 0
2 0
3 0
S o lid T u m o r s
% P
ha
go
cy
tos
is
A 549 A 431 O V 3 D L D S K 3
**
*
*
L ung
*****
E p id . O va ria n C o lo n B re a s t
-4 -3 -2 -1 0 1 2 3 4
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
P h a g o c y to s is o f P r im a ry A M L
T T I-6 2 1 (L o g n M )
Ph
ag
oc
yto
sis
In
de
x
E C 50 = 4 n M
Co
ntr
ol F
c
TT
I-621
Co
ntr
ol F
c
TT
I-621
Co
ntr
ol F
c
TT
I-621
Co
ntr
ol F
c
TT
I-621
Co
ntr
ol F
c
TT
I-621
0
1 0 0
2 0 0
3 0 0
4 0 0
Ph
ag
oc
yto
sis
In
de
x
A M L M D S M M B -A L L T -A L L
***
H e m a to lo g ic a l T u m o r s
*
*****
**
T T I-6 2 1
C o n tro l F c
0
1
2
3
4
3 0
4 0
S k in C a n c e r
% P
ha
go
cy
tos
is
A 375 G 3 6 S K 1 S K 2 8 W M
*
***
**
M C C M K L 1
M ela n om a M C C
Figure 2
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
C
0 2 0 4 0 6 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
D a y p o s t-E n g ra ftm e n t
Tu
mo
r V
olu
me
(m
m3
)
D o s in g w in d o w
D if fu s e L a rg e B C e ll L y m p h o m a
(T o le d o )
C o n tro l F c
S IR P F c
R itux im ab
***
***
0 2 0 4 0 6 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
B u rk it t L y m p h o m a
(R a ji)
D a y p o s t-E n g ra ftm e n t
Tu
mo
r V
olu
me
(m
m3
) D o s in g W in d o w
R itu x im a b
C o n tro l F c
S IR P F c***
***
0 2 0 4 0 6 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
B u rk it t L y m p h o m a
(N a m a lw a )
D a y p o s t-E n g ra ftm e n t
Tu
mo
r V
olu
me
(m
m3
)
D o s in g W in d o w
R itu x im a b
C o n tro l F c
S IR P F c***
***
D
E
A
B
C
E
T T I-6 2 1 C o n tro l F c
0
2 5
5 0
7 5
1 0 0
p = 3 x 10-8
In je c te d B o n e M a rro w
% A
ML
En
gra
ftm
en
t
T T I-6 2 1 C o n tro l F c
0
2 5
5 0
7 5
1 0 0
p = 0 .0 0 3
N o n -In je c te d B o n e M a rro w
%
AM
L E
ng
ra
ftm
en
t
T T I-6 2 1 C o n tro l F c
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
0 .6
0 .7
0 .8
0 .9
1 .0
1 .1
S p le e n
p = 0 .0 2% A
ML
En
gra
ftm
en
tT T I-6 2 1 C o n tro l F c
0
2 5
5 0
7 5
1 0 0
p = 0 .0 0 8
In je c te d B o n e M a rro w
% A
ML
En
gra
ftm
en
t
T T i-6 2 1 C o n tro l F c
0
2 5
5 0
7 5
1 0 0
p = 0 .0 0 3
N o n -In je c te d B o n e M a rro w
%
AM
L E
ng
ra
ftm
en
t
T T I-6 2 1 C o n tro l F c
0
1
2
3
4
5
6
7
8
S p le e n
p = 0 .0 0 0 4% A
ML
En
gra
ftm
en
t
0 2 0 4 0 6 0
0
5 0 0
1 0 0 0
1 5 0 0
D a y p o s t - E n g r a f t m e n t
Tu
mo
r V
olu
me
(m
m3
) D o s i n g W i n d o w
R i t u x im a b
C o n t r o l F c
S I R P F c
0 2 0 4 0 6 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
D a y p o s t - E n g r a f t m e n t
Tu
mo
r V
olu
me
(m
m3
)
D o s i n g W i n d o w
R i t u x im a b
C o n t r o l F c
S I R P F c
0 2 0 4 0 6 0 8 0 1 0 0
0
5 0 0
1 0 0 0
1 5 0 0
D a y p o s t-E n g ra ftm e n t
Tu
mo
r V
olu
me
(m
m3
)
S IR P F c
C o n tro l F c
R itu x im a b
D o s in g w in d o w
D
0 1 0 2 0 3 0 4 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
B L y m p h o m a
(A 2 0 )
D a y p o s t-E n g ra ftm e n t
Tu
mo
r V
olu
me
(m
m3
)
S IR P F c
V e h ic leD o s in g W in d o w ***
F
Figure 3
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
IgG
1 (
TT
I-621)
IgG
4
IgG
1 (
TT
I-621)
IgG
4
0
5 0
1 0 0
1 5 0
% M
ax
ph
ag
oc
yto
sis
M 1 M M 2 M
**
SIR
P
Fc (
IgG
4-m
ut)
SIR
P
Fc (
IgG
4)
SIR
P
Fc (
IgG
1)
(TT
I-621)
IgG
4-m
ut
Fc c
on
tro
l
IgG
1 F
c c
on
tro
l
0
2 5
5 0
7 5
1 0 0
In je c te d F e m u r
p < 0 .0 0 1
p < 0 .0 1p < 0 .0 0 1
% A
ML
En
gra
ftm
en
t
SIR
P
Fc (
IgG
4-m
ut)
SIR
P
Fc (
IgG
4)
SIR
P
Fc (
IgG
1)
(TT
I-621)
IgG
4-m
ut
Fc c
on
tro
l
IgG
1 F
c c
on
tro
l
0
2 5
5 0
7 5
1 0 0
p < 0 .0 0 1
p < 0 .0 0 1
N o n -In je c te d B M
p < 0 .0 5
%
AM
L E
ng
ra
ftm
en
t
SIR
P
Fc (
IgG
4-m
ut)
SIR
P
Fc (
IgG
4)
SIR
P
Fc (
IgG
1)
(TT
I-621)
IgG
4-m
ut
Fc c
on
tro
l
IgG
1 F
c c
on
tro
l
0
1
2
3
4
5
6
7
8
S p le e n
p < 0 .0 1
p < 0 .0 1
p < 0 .0 0 1
% A
ML
En
gra
ftm
en
t
A
B
Figure 4
C
No
dru
g
mIg
G1
Co
ntr
ol F
c
2D
3
B6H
12
TT
I-621
0
2 0
4 0
6 0
8 0
% P
ha
go
cy
tos
is
****
****
**
B lo c k a d e o f th e C D 4 7 -S IR P in te ra c t io n : N o Y e s Y e s
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
A
0 .0 1 0 .1 1 1 0 1 0 0 1 0 0 0 1 0 0 0 0
0
1
2
3
4
5
6
7
2 D 3
B 6 H 1 2
B R IC 1 2 6
5 F 9
C o n c e n tra t io n (n M )
He
ma
gg
luti
na
tio
n S
co
re
(me
an
S
E)
T T I-6 2 1
B
TT
I-621
BR
IC126
2D
3
CC
2C
6
B6H
12
5F
9
hIg
G1 F
c
mIg
G1
mIg
G2b
0
5 0 0
1 0 0 0
1 5 0 0
1 0 0 ,0 0 0
2 0 0 ,0 0 0
3 0 0 ,0 0 0
C D 47 m A bs C o n tro ls
Me
an
Flu
ore
sc
en
ce
In
ten
sit
y
C
TTI-621 BRIC126 2D3 CC2C6 B6H12 5F9
Fluorescence Intensity
Figure 5
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
Figure 6
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700
Published OnlineFirst November 17, 2016.Clin Cancer Res Penka S Petrova, Natasja N Viller, Mark Wong, et al. Erythrocyte BindingInhibitor with Broad Anti-Tumor Activity and Minimal
Fc): A CD47-Blocking Innate Immune CheckpointαTTI-621 (SIRP
Updated version
10.1158/1078-0432.CCR-16-1700doi:
Access the most recent version of this article at:
Material
Supplementary
http://clincancerres.aacrjournals.org/content/suppl/2016/11/16/1078-0432.CCR-16-1700.DC1
Access the most recent supplemental material at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2016/11/19/1078-0432.CCR-16-1700To request permission to re-use all or part of this article, use this link
Research. on May 31, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on November 17, 2016; DOI: 10.1158/1078-0432.CCR-16-1700